IPO - Cidara Therapeutics, Inc.

Form Type: CORRESP

Filing Date: 2024-12-30

Corporate Action: Ipo

Type: New

Accession Number: 000119312524286899

Filing Summary: Cidara Therapeutics, Inc. requested the U.S. Securities and Exchange Commission to take action for its Registration Statement on Form S-1, filed on December 23, 2024, to become effective on December 31, 2024, at 4:00 p.m. Eastern Time or as soon thereafter as practicable. This step is in preparation for an initial public offering, which indicates the company is advancing its efforts to raise capital in the public markets. The request was made through a formal communication addressed to the SEC, highlighting the company's intention to confirm the effective date post-approval with its legal counsel.

Form Type: S-1

Filing Date: 2024-12-23

Corporate Action: Ipo

Type: New

Accession Number: 000119312524284233

Filing Summary: Cidara Therapeutics, Inc. has filed a registration statement with the SEC to offer up to $100 million in shares as part of an initial public offering (IPO). This opportunity is part of the company’s efforts to expand its capital base to support the development of its therapeutics pipeline, particularly focusing on its lead product candidate Rezafungin, which is aimed at treating serious fungal infections. The offering is underwritten by Cantor Fitzgerald, and the funds raised will also be used for the advancement of their research and development efforts. The company emphasizes its strategic partnerships with pharmaceuticals to enhance its market positioning and product delivery. Details regarding pricing, number of shares, and specific underwriter arrangements are expected to be provided in subsequent filings as the offering progresses.